Monoclonal antibodies in the management of asthma: Dead ends, current status and future perspectives

Patients with moderate-to-severe asthma may now be treated using a variety of monoclonal antibodies that target key inflammatory cytokines involved in disease pathogenesis. Existing clinical data on anti-IgE, anti-IL-5 and other immunological pathways indicate these therapies to offer reduced exacer...

Descripción completa

Detalles Bibliográficos
Autores principales: Kardas, Grzegorz, Panek, Michał, Kuna, Piotr, Damiański, Piotr, Kupczyk, Maciej
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Frontiers Media S.A. 2022
Materias:
Immunology
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9763885/
https://www.ncbi.nlm.nih.gov/pubmed/36561741
http://dx.doi.org/10.3389/fimmu.2022.983852

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9763885/
https://www.ncbi.nlm.nih.gov/pubmed/36561741
http://dx.doi.org/10.3389/fimmu.2022.983852

Ejemplares similares